Dr.HARIKA REGANI

Dr. SANTOSH G. HONAVAR, Dr. KAUSTUBH MULAY

Abstract

To analyze the outcomes of secondary episcleral plaque brachytherapy in retinoblastoma (RB) by a retrospective interventional case series of RB treated with Ru106 PB from February 2013 to December 2019. The outcome measures were life salvage and eye salvage. Causes of treatment failure were evaluated.

Results: 55 eyes of 53 consecutive RB patients were managed by secondary Ru106 brachytherapy. ICRB Groups were E (10, 18%), D (20, 36%). C (1.8%) and B (6, 10%). Age at the treatment was 28.8+18.9m (range, 0-72). Mean tumor height was 4.7+0.9 mm (range, 3-6), and the mean tumor apex dose was 4500 cGy. There was excellent response in 40 eyes (72%), modest response in 10 (18%) and poor response in 5 (9%); 11 (20%) eyes had tumor recurrence needing focal therapy. Enucleation was done in 14 eyes and the most common cause was unresolving vitreous hemorrhage secondary to necrotic tumor (50%). Secondary Ru106 brachytherapy is an excellent option for eye salvage for recurrent or refractory RB.